CAR-macrophage has promising prospect in treating solid tumors, due to its high infiltration into tumors, and its dual roles in phagocytosis and immune modulation. Here we show the clinical results of CAR-macrophage treatment of two ovarian cancer patients. The CAR-macrophages were produced by introducing a mesothelin targeting CAR to patients’ primary peripheral blood mononuclear cell-derived macrophages, and the products were infused to patients intravenously. Our data show good safety of the infusion product, and the efficacy can be further improved. Intraperitoneal infusion of CAR-macrophages has proven effective in treating intraperitoneal tumors in a preclinical model, paving the way for demonstrating proof-of-concept clinical efficacy of CAR-macrophages in the treatment of intraperitoneal tumors.

中文翻译：

---

靶向间皮素的自体嵌合抗原受体巨噬细胞的临床研究显示卵巢癌治疗的安全性


CAR 巨噬细胞在治疗实体瘤方面具有广阔的前景，因为它对肿瘤的高度浸润性，以及它在吞噬作用和免疫调节中的双重作用。在这里，我们展示了 CAR 巨噬细胞治疗两名卵巢癌患者的临床结果。通过将靶向 CAR 的间皮素引入患者的原代外周血单核细胞来源的巨噬细胞来产生 CAR 巨噬细胞，并将产品静脉输注给患者。我们的数据表明，输液产品的安全性很好，疗效可以进一步提高。在临床前模型中，CAR 巨噬细胞的腹膜内输注已被证明可有效治疗腹膜内肿瘤，为证明 CAR 巨噬细胞治疗腹膜内肿瘤的概念验证临床疗效铺平了道路。